-
Three Steps can Help Companies Speed FDA approval of New Drugs Opens in a new window)
The main reason for delays and extensions is that sponsors submit their applications too soon. -
Uncovering the Potential of Advanced Analytics in International Price Management Opens in a new window)
How can pharmaceutical companies successfully apply advanced analytics?Comments
-
‘Held to Ransom’: Pfizer Demands Governments Gamble with State Assets to Secure Vaccine Deal Opens in a new window)
In the case of one country, demands made by the pharmaceutical giant led to a three-month delay in a vaccine deal being agreed.Comments
-
COVID-19 has Shown How Big Pharma is Broken Opens in a new window)
Though they were warned, pharmaceutical companies refused to invest in coronavirus research until it was too late.Comments
-
Industrial Innovators 2020
The top biopharmaceutical investors in the world.Comments
-
Waiting for Big Pharma’s Coronavirus Profits to Impress Wall Street Opens in a new window)
Vaccines and therapeutics for Covid-19 have been an unexpected windfall for the drug industry, but Wall Street is less enthusiastic about cash windfalls.Comments
-
Insiders at Covid-19 Vaccine Makers Sold Nearly $500 Million of Stock Last Year Opens in a new window)
In dollar terms, much of the sales came at a single company, Moderna, maker of one of two Covid-19 vaccines authorized for use in the U.S. Executives and a director there sold more than $321 million of their stock in more than 700 transactions.Comments
-
How a Powerful Corporate Consulting Firm Helped Create the Opioid Epidemic
The opioids crisis that has taken hundreds of thousands of American lives has received less attention in the pandemic, but drug overdoses and deaths have grown during the last year.Comments
-
Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported? Opens in a new window)
Are manufacturing method patents — patents not on a pharmaceutical drug itself, but on a method of production of a drug — warranted intellectual property protections, or groundless obstacles to competition?Comments
-
Vice-President Vestager Forces SA Drug Firm Aspen to Slash Cancer Drug Prices
Statement by Executive Vice-President Vestager on the Commission decision to accept commitments by Aspen to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns.Comments
-
Bristol-Myers, Sanofi Ordered to Pay Hawaii $834 Million Over Plavix Warning Label Opens in a new window)
Bristol-Myers and Sanofi still face a similar lawsuit over Plavix by the state of New Mexico.Comments
-
Big Pharma Wants to Help Poor Countries Fight Covid-19—But They’d Better Pay Opens in a new window)
Big pharma has been essential in the race to fight Covid-19. In exchange, their work to end Covid-19 has rewarded pharmaceutical companies rather handsomely.Comments
-
Drug Companies Seek Billion-Dollar Tax Deductions From Opioid Settlement Opens in a new window)
Four companies that agreed to pay a combined $26 billion to settle claims about their roles in the U.S. opioid crisis plan to deduct some of those costs from their taxes and recoup around $1 billion apiece.Comments
-
Understanding Drug Pricing in the US
A Mount Sinai Morningside and Mount Sinai West Department of Medicine Grand Rounds presented by Deborah Korenstein, MD, Chief, General Medicine Service, Memorial Sloan Kettering Cancer Center.Comments
-
Amgen Loses Bid to Revive Patents for Cholesterol Drug Repatha Opens in a new window)
A victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.Comments
Comments